| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| CAVA GROUP, INC. | Director | Common Stock | 9,507,990 | $1,420,493,706 | $149.40 | 05 Dec 2024 | Direct |
| LEXICON PHARMACEUTICALS, INC. | Director, 10%+ Owner | Series B Convertible Preferred Stock | 408,435 | $26,548,255 | $65.00 | 17 Feb 2026 | Indirect |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| LXRX | LEXICON PHARMACEUTICALS, INC. | 17 Feb 2026 | 1 | +$2,683,823 | 4 | Director, 10%+ Owner | 19 Feb 2026, 16:50 |
| CAVA | CAVA GROUP, INC. | 05 Dec 2024 | 0 | $0 | 3 | Director | 16 Dec 2024, 19:03 |
| LXRX | LEXICON PHARMACEUTICALS, INC. | 05 Dec 2024 | 0 | $0 | 3 | Director, 10%+ Owner | 16 Dec 2024, 19:00 |